Join our daily newsletter At The Bell to receive exclusive market insights
- Creso Pharma’s (CPH) subsidiary Halucenex Life Sciences has entered a binding supply of goods agreement with Optimi Health for EU-GMP grade psilocybin mushrooms
- The automatically renewing one year agreement, will see Optimi supply its whole dried mushroom fruiting bodies to CPH
- Halucenex will then test the product’s quality and physical characteristics before negotiating for further purchases
- The partnership will have the potential to provide Halucanex with a consistent supply of standardised EU-GMP grade psilocybin
- Shares have ended the day trading steady at 5.3 cents
Creso Pharma’s (CPH) subsidiary Halucenex Life Sciences has entered a binding supply of goods agreement with Optimi Health for EU-GMP grade psilocybin mushrooms.
The automatically renewing one year agreement, will see Optimi supply its whole dried mushroom fruiting bodies to CPH.
The initial products will be provided for free, but will be subject to a handling fee of C$1500 (A$1643).
Halucenex will then test the product’s quality and physical characteristics before negotiating for further purchases.
If testing protocols are successful, Halucanex then aims to develop the product to focus on treatments for post traumatic stress disorder and anxiety.
The partnership will have the potential to provide Halucanex with a consistent supply of standardised EU-GMP grade psilocybin.
Managing Director Bill Fleming said the agreement is crucial for future product development.
“Optimi are an incredibly respected partner in the psychedelics sector and one of the few companies that have secured an amendment to its Health Canada’s Dealer’s Licence, allowing them to possess a large quota of dried psilocybe mushrooms,” he said.
Shares ended the day trading steady at 5.3 cents.
